Apollo Hospitals Partners with Precisio Biotix on Lysin-Based Antimicrobials to Combat AMR
Event summary
- Apollo Hospitals collaborates with Precisio Biotix to develop and clinically validate lysin-based antimicrobials in India, focusing on infectious diseases with limited treatment options.
- Lysins are precision antimicrobials that target pathogens without contributing to antimicrobial resistance (AMR).
- The partnership will include translational research, clinical validation, and potential deployment pathways across Apollo's network.
- A white paper on lysin-based therapies and AMR management in India is planned, along with compassionate use/expanded access clinical programs for prosthetic joint infections.
The big picture
This collaboration underscores the growing urgency in combating antimicrobial resistance through innovative, targeted therapies. Lysins represent a promising alternative to conventional antibiotics, offering a mechanism that avoids contributing to AMR. Apollo Hospitals' extensive healthcare platform provides Precisio Biotix with a robust infrastructure for clinical validation and deployment, potentially accelerating the adoption of next-generation antimicrobials in India and beyond.
What we're watching
- Clinical Validation
- The pace at which lysin-based therapies demonstrate efficacy in real-world clinical settings will determine their adoption rate.
- Regulatory Approval
- Whether Precisio Biotix can secure regulatory approvals for its novel antimicrobials in India and other key markets.
- Market Expansion
- How Apollo Hospitals leverages its extensive network to scale the deployment of lysin-based therapies across different infectious disease areas.
Related topics